test

Flynn Management LLC, its general partner

@Deerfield Management Company, L.p. (series C)

Latest period2024 - Q3ReportedManaged Assets$6.693BTotal holdings443
Assets growth rate11.36%Assets growth rate (2-Q avg)7.96%Continuous growth in asset value4 quarters

Portfolio positions

This chart displays the top 10 holdings in Deerfield Management Company, L.p. (series C)'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 443 positions.

Assets under management

The assets under management (AUM) of Deerfield Management Company, L.p. (series C) over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 6.693B in assets, with a quarterly growth rate of 11.36% and a 2-quarter average growth rate of 7.96%. The portfolio is managed by Flynn Management LLC, its general partner, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
CATXPerspective Therapeutics Inc
Recent Activity
0.57%
$37.617M
2.818M shares@ $13.35 avg price
GPCRStructure Therapeutics Inc
Recent Activity
0.56%
$37.061M
844,407 shares@ $43.89 avg price
DAWNDay One Biopharmaceuticals I
Recent Activity
Decreased -10.44%
0.55%
$36.465M
2.618M shares@ $13.93 avg price
TXG10x Genomics Inc
Recent Activity
Increased 152.76%
0.51%
$34.072M
1.509M shares@ $22.59 avg price
CGONCg Oncology Inc
Recent Activity
Increased 96.23%
0.48%
$32.097M
850,695 shares@ $37.73 avg price
DCGODocgo Inc
Recent Activity
Increased 25.99%
0.45%
$30.1M
9.066M shares@ $3.32 avg price
FHTXFoghorn Therapeutics Inc
Recent Activity
Increased 20.23%
0.43%
$28.19M
3.028M shares@ $9.32 avg price
MREOMereo Biopharma Group Plc
Recent Activity
0.42%
$27.58M
6.71M shares@ $4.11 avg price
SVRASavara Inc
Recent Activity
New Position
0.41%
$27.415M
6.466M shares@ $4.24 avg price
INMDInmode Ltd
Recent Activity
Increased 35.32%
0.4%
$26.759M
1.579M shares@ $16.96 avg price